Truist lowered the firm’s price target on Legend Biotech (LEGN) to $71 from $88 and keeps a Buy rating on the shares after its Q1 results. Carvykti sales rose 10% q/q, with U.S. growth modest at 5%, and the firm notes that the more robust acceleration it had hoped for is now likely to come in the second half of the year vs. Q2 previously, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s Carvykti: Strong Growth Prospects and Strategic Expansion Justify Buy Rating
- Legend Biotech’s Strong Market Position and Growth Potential Drive Buy Rating
- Legend Biotech’s Q1 2025: Strong CAR-T Sales and Expansion
- Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
- Legend Biotech Reports Strong Q1 2025 Results and Expands CARVYKTI® Reach